InvestorsHub Logo
Followers 242
Posts 12273
Boards Moderated 0
Alias Born 08/14/2003

Re: pgsd post# 525996

Sunday, 10/30/2022 1:44:02 AM

Sunday, October 30, 2022 1:44:02 AM

Post# of 698657
My view of BP isn't one of them killing great ideas, rather they're like buzzards circling a target waiting for it to die. If they die, they'll swoop in and purchase what they've developed for a song. If they survive, they'll pay fair market value to acquire or partner.

My point is, they permit biotech's and research institutions to be the developers of most of the biggest advancements in medicine, but in the end they acquire practically all the great ideas that are developed.

If you ask people about great drugs and who developed them, most will answer that they were developed by the company marketing them. Take Kadcyla, it's a conjugate developed from Herceptin, both are owned by Genentech which is owned by Roche. Herceptin is actually Trastuzumab and it was originally developed at City of Hope. Kadcyla was referred to as T-DM1, the T is Trastuzumab and the -DM1 is the linker and effector molecule developed by IMGN. Neither Roche or Genentech developed any part of Kadcyla but most people would say they did. In all honesty Genentech did push IMGN to improve on their linker and effector molecule to make a more consistent product, but it's still IMGN's technology.

I believe that BP will only be too happy to partner or acquire NWBO. In that NWBO owns FlaskWorks they'll be partnering or acquiring far more than a couple vaccines from NWBO. The FlaskWorks patents may well become the basis for many personal products, each may be somewhat different from others, but they'll all utilize FlaskWorks patents and NWBO or whoever purchases it will earn money from what's utilizing it whether it's a product that's owned by the BP, or by a competitor. It's great to make money from the efforts of others.

Gary
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News